GUILLAIN-BARRE SYNDROME (GBS)
Guillain-Barre Syndrome (“GBS”) or acute inflammatory demyelinating polyneuropathy (“AIDP”) is a rare disorder where the body’s immune system attacks myelin, the protective coating of nerves, leading to injuries in the underlying nerves where the demyelination occurred in the peripheral nervous system. The first symptoms of GBS are generally weakness and tingling in the extremities. These symptoms can spread rapidly to affect all sensory, motor and autonomic nerves. In severe cases, paralysis can occur leading to potentially life threatening respiratory and cardiac compromise.
GBS can affect both adults and children. While the causes of GBS remain unknown, the onset of GBS has been associated with bacterial and viral infections, surgery and vaccination. The symptoms of GBS generally appear a few days or weeks after infection. Progression of symptoms after onset can occur over the course of hours, days, or weeks.
Recovery can be complete, however, a significant number of patients suffer residual symptoms that range from mild to severe. In rare circumstances, future relapses can occur.
To date, GBS is one of the most compensated injuries in the Vaccine Program.
In Peugh v. Secretary of Health and Human Services, petitioner was granted entitlement for the onset of Guillain Barre Syndrome (“GBS”) following a hepatitis B vaccine administration.
For more information about this and other representative cases tried by Attorney Chin-Caplan, click here or see her Representative Cases above.